603998 logo

Hunan Fangsheng Pharmaceutical Co., Ltd. Stock Price

SHSE:603998 Community·CN¥5.3b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

603998 Share Price Performance

CN¥0
-9.51 (-100.00%)
CN¥0
-9.51 (-100.00%)
Price CN¥0

603998 Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Undervalued established dividend payer.

2 Risks
4 Rewards

Hunan Fangsheng Pharmaceutical Co., Ltd. Key Details

CN¥1.7b

Revenue

CN¥511.1m

Cost of Revenue

CN¥1.2b

Gross Profit

CN¥876.4m

Other Expenses

CN¥295.4m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Apr 25, 2026
0.67
69.63%
17.55%
29.0%
View Full Analysis

About 603998

Founded
2002
Employees
1807
CEO
Xiaoli Zhou
WebsiteView website
www.fangsheng.com.cn

Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs, and anti-infective drugs. The company's main products include Xuesetong dispersible tablets, Xuesetong tablets, Garcinia bone-strengthening tablets, Dieda Huoxue capsules, Lysine Vitamin B12 granules, Cefuroxime tablets, Jinying capsules, Pudilan anti-inflammatory tablets, Xiaoer Jingxing cough granules, Ezetimibe tablets, Xuanqi bone-strengthening tablets, Qiangli Loquat Paste (honey-refined), and Qiangli Loquat Dew and others. It also offers other businesses, such as medical services, pharmaceutical commerce, and drug sales. The company was founded in 2002 and is based in Changsha, China.

Recent 603998 News & Updates

Recent updates

No updates